Cargando…

T190. COMPARABILITY OF PATIENT AND STUDY CHARACTERISTICS IN RANDOMIZED CONTROLLED TRIALS ON PHARMACOTHERAPY AND PSYCHOTHERAPY FOR POSITIVE SYMPTOMS OF SCHIZOPHRENIA: A SYSTEMATIC REVIEW

Abstract not included.

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Session III
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234475/ http://dx.doi.org/10.1093/schbul/sbaa029.750

Ejemplares similares

T91. THE POSITIVE AND NEGATIVE SYNDROME SCALE SUPERIOR TO A SELF-REPORT QUESTIONNAIRE IN THE PHARMACOTHERAPY MONITORING AND OUTCOME SURVEY
por: Bartels-Velthuis, Annegien, et al.
Publicado: (2020)

T175. THE GUT-MICROBIOTA AS A TARGET FOR THE TREATMENT OF NEGATIVE SYMPTOMS OF SCHIZOPHRENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF CONTROLLED TRIALS OF ADD-ON STRATEGIES
por: Minichino, Amedeo, et al.
Publicado: (2020)

T205. LUMATEPERONE IN THE TREATMENT OF SCHIZOPHRENIA: EVALUATION OF EXTRAPYRAMIDAL AND MOTOR SYMPTOMS IN 4 LATE-PHASE CLINICAL TRIALS
por: Durgam, Suresh, et al.
Publicado: (2020)

T110. CLINICAL CHARACTERISTICS OF FORMAL THOUGHT DISORDER IN SCHIZOPHRENIA
por: Lee, Euijin, et al.
Publicado: (2020)

T99. HARNESSING DIGITAL TECHNOLOGIES TO ASSESS AND TREAT COGNITIVE SYMPTOMS IN SCHIZOPHRENIA
por: Shvetz, Cecelia, et al.
Publicado: (2020)

T193. THE ROLE OF METACOGNITION ON NEGATIVE SYMPTOMS: A PSYCHOLOGICAL MODEL FOR DIMINISHED EXPRESSION IN SCHIZOPHRENIA
por: García-Mieres, Helena, et al.
Publicado: (2020)

T144. CORRELATION BETWEEN CEREBELLAR-PREFRONTAL NETWORK CONNECTIVITY AND NEGATIVE SYMPTOMS ASSOCIATED WITH THE STAGES OF SCHIZOPHRENIA
por: Zhang, Bin, et al.
Publicado: (2020)

T89. THE RELIABILITY OF THE CORE NEGATIVE SYMPTOMS SCALE OF SCHIZOPHRENIA USING THE STANDARD FOR CLINICIANS’ INTERVIEW IN PSYCHIATRY (SCIP)
por: Aboraya, Ahmed
Publicado: (2020)

T53. NEUROPHYSIOLOGICAL AND BEHAVIORAL EFFECTS OF THE STIMULATION OF NICOTINIC RECEPTORS AND NON-INVASIVE BRAIN STIMULATION IN PATIENTS WITH SCHIZOPHRENIA: STUDY DESIGN AND METHODOLOGY OF A RANDOMIZED CONTROLLED TRIAL
por: Güler, Duygu, et al.
Publicado: (2020)

T185. OLIGOPEPTIDASES IN SCHIZOPHRENIA
Publicado: (2020)

T188. THE CLINICAL SCIENCE OF TRANSCRANIAL DIRECT CURRENT STIMULATION STUDIES IN SCHIZOPHRENIA: SYSTEMATIC REVIEW AND META-ANALYSIS
por: Mervis, Joshua, et al.
Publicado: (2020)

T28. BENEFITS AND HARMS OF ANTIPSYCHOTICS IN THE TREATMENT OF CHILDREN AND ADOLESCENTS WITH SCHIZOPHRENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Hagi, Katsuhiko, et al.
Publicado: (2020)

M190. USE OF NULL PRONOUNS IN SCHIZOPHRENIA
por: Chaves, Monica, et al.
Publicado: (2020)

T129. PHARMACOLOGICAL INTERVENTIONS IN TRIALS OF PEOPLE WITH SCHIZOPHRENIA: A REGISTER-BASED CLASSIFICATION OF SEVENTY YEARS OF RESEARCH
por: Shokraneh, Farhad
Publicado: (2020)

T149. CARDIOVASCULAR RISK AND VASCULAR AGE IN ADULTS WITH SCHIZOPHRENIA COMPARED TO A HEALTHY POPULATION: DATA FROM CORTEX-SP STUDY
por: Tous-Espelosin, Mikel, et al.
Publicado: (2020)

T79. BALANCING EFFECTS WITH SIDE-EFFECTS: EXAMINING COMPARATIVE METABOLIC CONSEQUENCES OF 18 ANTIPSYCHOTICS IN TREATMENT OF SCHIZOPHRENIA USING NETWORK META-ANALYSIS
por: Pillinger, Toby, et al.
Publicado: (2020)

T59. ACOUSTIC SPEECH MARKERS FOR SCHIZOPHRENIA
por: de Boer, Janna, et al.
Publicado: (2020)

T2. ADVERSE CHILDHOOD EXPERIENCES IN PEOPLE WITH SCHIZOPHRENIA
por: Klaunig, Mallory, et al.
Publicado: (2020)

T90. QUANTIFYING THE CORE DEFICIT IN CLASSICAL SCHIZOPHRENIA
por: Rathnaiah, Mohanbabu, et al.
Publicado: (2020)

T197. TREATMENT STRATEGIES FOR ULTRA-RESISTANT SCHIZOPHRENIAS
por: Vasiliu, Octavian
Publicado: (2020)

T11. CORONARY ARTERY CALCIFICATION IN PEOPLE WITH SCHIZOPHRENIA
por: Trab, Trine, et al.
Publicado: (2020)

T246. RISK FACTORS FOR PSYCHOTIC RELAPSE IN CHRONIC SCHIZOPHRENIA AFTER DOSE-REDUCTION OR DISCONTINUATION OF ANTIPSYCHOTICS: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Bogers, Jan, et al.
Publicado: (2020)

T214. ANTIPSYCHOTIC TREATMENT PATTERNS AND EFFECTS DURING THE EARLY YEARS AMONG 316 NEWLY DIAGNOSED PATIENTS WITH SCHIZOPHRENIA FROM THE OPUS TRIAL
por: Albert, Nikolai, et al.
Publicado: (2020)

T19. GLUTAMATE AND RESPONSE TO CLOZAPINE IN TREATMENT RESISTANT SCHIZOPHRENIA
por: Egerton, Alice, et al.
Publicado: (2020)

T98. CHARACTERIZING THE CLINICAL COURSE IN SCHIZOPHRENIA WITH DIGITAL PHENOTYPING
por: Torous, John, et al.
Publicado: (2020)

T8. ANTIPSYCHOTIC TREATMENT AND EYE MOVEMENT ABNORMALITIES IN SCHIZOPHRENIA
por: Takahashi, Junichi, et al.
Publicado: (2020)

T77. ASSOCIATION BETWEEN INTRACELLULAR INFECTIOUS AGENTS AND SCHIZOPHRENIA
por: Kwon, Young-Joon, et al.
Publicado: (2020)

T132. RETINAL GANGLION CELLS DYSFUNCTIONS IN SCHIZOPHRENIA PATIENTS
por: Bernadin, Florent, et al.
Publicado: (2020)

T47. GUANFACINE AUGMENTATION OF ATTENTIONAL FUNCTIONING IN THE SCHIZOPHRENIA SPECTRUM
Publicado: (2020)

T41. SAFETY PROFILE OF ADJUNCTIVE PIMAVANSERIN IN THE ENHANCE STUDY, A PHASE 3 TRIAL FOR THE POTENTIAL TREATMENT OF SCHIZOPHRENIA IN PATIENTS WITH AN INADEQUATE RESPONSE TO ANTIPSYCHOTIC TREATMENT
por: Bugarski-Kirola, Dragana, et al.
Publicado: (2020)

T228. SOCIAL REWARD REACTIVITY AND SENSITIVITY IN SCHIZOPHRENIA SPECTRUM CONDITIONS
por: Aldridge-Waddon, Luke, et al.
Publicado: (2020)

T16. SCHIZOPHRENIA SPECTRUM DISORDER: DEPRESSION TRAJECTORIES AND IMMUNE MARKERS
por: Hoprekstad, Gunnhild, et al.
Publicado: (2020)

T13. CORNEAL CONFOCAL MICROSCOPY DETECTS NEURAL CHANGES IN SCHIZOPHRENIA
por: Woodruff, Peter, et al.
Publicado: (2020)

T83. SUBSTANCE-INDUCED PSYCHOSIS LINKED TO BOTH INFECTIONS AND SCHIZOPHRENIA
por: Hjorthøj, Carsten, et al.
Publicado: (2020)

T176. INSIGHTS INTO THE ROLE OF ORAL AND GUT MICROBIOME IN THE PATHOGENESIS OF SCHIZOPHRENIA
por: Ghorbani, Mahin, et al.
Publicado: (2020)

T45. THE EFFICACY AND HETEROGENEITY OF ANTIPSYCHOTIC RESPONSE IN SCHIZOPHRENIA: A META-ANALYSIS
por: McCutcheon, Rob, et al.
Publicado: (2020)

T93. RESHAPING THE DIAGNOSTIC BORDERS OF SCHIZOPHRENIA: THE LOOK OF HISTORY OF PSYCHIATRIC PRACTICES
por: Clauss, Julie, et al.
Publicado: (2020)

T15. MISMATCH NEGATIVITY INDICES AS A PROGNOSTIC FACTOR FOR REMISSION IN SCHIZOPHRENIA
por: Shim, Se-Hoon, et al.
Publicado: (2020)

T62. A COMPUTATIONAL ANALYSIS OF MOTIVATIONAL DEFICITS IN SCHIZOPHRENIA SPECTRUM DISORDERS
por: Waltz, James, et al.
Publicado: (2020)

T222. IMPAIRED COST-BENEFIT COMPUTATION IN SOCIAL CONTEXT IN PATIENTS WITH SCHIZOPHRENIA
por: Yan, Chao, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3fvaut3l02sikslb88m8u60be2